On this page
Back to topIQVIA IQV
IQVIA is the 252nd largest S&P 500 company by market cap, worth $44.8 billion. Its board has 10 directors, 8 of them independent. 9 other officers are on file. At 30 Jun 2026, Vanguard was its largest institutional holder, with 12.1% of the company.
- Chair and CEO
- Ari Bousbib
- Sector
- Health CareLife Sciences Tools & Services
- Headquarters
- Durham, North Carolina
- Founded
- 1982
- Market cap
- $44.8B
- 252nd largest, 6 Nov 2026 close
- Price to sales
- 2.8
- Market cap over revenue
- Per employee
- $482K
- Market cap over employees
- Connections
- 3
- Companies sharing people
Financials
Latest quarter
Third Quarter 2026 figures from IQVIA's earnings release.
Filed 27 Oct 2026
- Revenue
- $4.4B
- Up 8.0% year over year
- Net income
- $350M
- Up 5.7% year over year
- Diluted EPS
- $2.10
- Up 8.8% year over year
Reported figures
Figures from the release, against the same period a year earlier.
| Figure | Value | Change |
|---|---|---|
| Revenue | $4.4B | +8.0% |
| GAAP Net Income | $350M | +5.7% |
| Adjusted EBITDA | $1.0B | +8.7% |
| GAAP Diluted Earnings per Share | $2.10 | +8.8% |
| Adjusted Diluted Earnings per Share | $3.34 | +11% |
| Adjusted Net Income | $557M | +8.2% |
| Operating Cash Flow | $825M | -9.1% |
| Free Cash Flow | $667M | -14% |
| Figure | Value | Change |
|---|---|---|
| Commercial Solutions revenue | $1.8B | +6.9% |
| R&D Solutions revenue | $2.6B | +8.7% |
| Figure | Value | Change |
|---|---|---|
| R&D Solutions Net New Bookings | $3.2B | +15% |
| Book-to-bill ratio | 1.2 | - |
| Last-twelve-month net new bookings | $11.7B | +14% |
| R&DS contracted backlog | $32.6B | - |
| Next-twelve-month revenue from backlog | $9.4B | +10% |
| Figure | Value | Change |
|---|---|---|
| Revenue guidanceFull-year 2026 guidance | $17.4B | - |
| Adjusted EBITDA guidanceFull-year 2026 guidance | $4.0B | - |
| Adjusted Diluted Earnings per Share guidanceFull-year 2026 guidance | $12.95 | - |
Financial history
Twelve months to 30 Sep 2026, from IQVIA's quarterly filings.
Quarters since Dec 2021
- Revenue
- $17.3B
- Up 8.8% on the year before
- Net income
- $1.4B
- 8.1% of revenue
- Free cash flow
- $2.1B
- Operating cash flow less capital spending
- P/E
- 32.1
- Market cap over net income
Quarterly results
Each quarter's revenue, net income and free cash flow.
Dec 2021 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $4.4B | $350M |
| Jun 2026 | $4.4B | $256M |
| Mar 2026 | $4.2B | $274M |
| Dec 2025 | $4.4B | $514M |
| Sep 2025 | $4.1B | $331M |
| Jun 2025 | $4.0B | $266M |
| Mar 2025 | $3.8B | $249M |
| Dec 2024 | $4.0B | $437M |
| Sep 2024 | $3.9B | $285M |
| Jun 2024 | $3.8B | $363M |
| Mar 2024 | $3.7B | $288M |
| Dec 2023 | $3.9B | $469M |
| Sep 2023 | $3.7B | $303M |
| Jun 2023 | $3.7B | $297M |
| Mar 2023 | $3.7B | $289M |
| Dec 2022 | $3.7B | $227M |
| Sep 2022 | $3.6B | $283M |
| Jun 2022 | $3.5B | $256M |
| Mar 2022 | $3.6B | $325M |
| Dec 2021 | $3.6B | $318M |
Per employee
Twelve months to 30 Sep 2026, over 93,000 employees in IQVIA's latest 10-K.
- Revenue
- $186K
- Operating profit
- $24K
- 12.8% of revenue
- Net income
- $15K
- 8.1% of revenue
IQVIA's market cap since May 2013
Marked weeks are changes in the share count, such as a merger, not market moves.
Weekly, up to 6 Nov 2026
| Week ending | Market cap |
|---|---|
| 6 Nov 2026 | $44.8B |
| 26 Dec 2025 | $38.6B |
| 27 Dec 2024 | $36.2B |
| 29 Dec 2023 | $42.2B |
| 30 Dec 2022 | $38.1B |
| 31 Dec 2021 | $53.9B |
| 25 Dec 2020 | $33.7B |
| 27 Dec 2019 | $30.0B |
| 28 Dec 2018 | $23.0B |
| 29 Dec 2017 | $20.7B |
| 30 Dec 2016 | $18.7B |
| 25 Dec 2015 | $8.6B |
| 26 Dec 2014 | $7.8B |
| 27 Dec 2013 | $6.0B |
Download IQVIA's data as JSON, with the weekly market caps in billions of dollars from 10 May 2013.
Board and leadership
Board and officers
3 people here also hold roles at other S&P 500 companies.
Board from the proxy filed 27 Feb 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (10) | |||||
| Ari BousbibChair; OfficerNot independent · since 2016Also at The Home Depot | |||||
| Carol BurtDirectorIndependent · since 2019 · Audit, Leadership Development and Compensation (chair)Principal, Burt-Hilliard Investments; Senior Advisor, Consonance Capital PartnersAlso at ResMed | |||||
| John G. DanhaklDirectorIndependent · since 2016 · Leadership Development and Compensation, Nominating and GovernanceManaging Partner, Leonard Green & Partners, L.P.Other boards: Life Time Group Holdings and Mister Car Wash | |||||
| Jim FasanoDirectorIndependent · since 2016 · Audit (chair), Leadership Development and CompensationRetired Managing Director, CPP Investment Board; Adjunct Professor, University of Chicago Booth School of Business | |||||
| Colleen A. GogginsDirectorIndependent · since 2017 · Audit, Nominating and Governance (chair)Retired Member of Executive Committee and Worldwide Chair of Consumer Group, Johnson & JohnsonOther boards: Bayer AG | |||||
| William G. Kaelin Jr.DirectorIndependent · since 2025Senior Physician-Scientist, Brigham and Women's Hospital; Sidney Farber Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical SchoolAlso at Eli Lilly | |||||
| John M. LeonardLead Independent DirectorIndependent · since 2015 · Audit, Nominating and GovernancePresident and Chief Executive Officer, Intellia Therapeutics, Inc.Other boards: Intellia Therapeutics | |||||
| Leslie Wims MorrisDirectorIndependent · since 2022 · Nominating and GovernanceChief Executive Officer, Chase Auto, JP Morgan Chase | |||||
| Sheila A. StampsDirectorIndependent · since 2022 · AuditRetired Managing Director, Bank of AmericaOther boards: MFA Financial | |||||
| Morris Leslie WimsDirector | |||||
| Officers (9) | |||||
| Ronald E. BruehlmanEVP & Chief Financial OfficerLast filed 10 Feb 2026 | |||||
| James G. BerkshireEVP, Global Infrastructure and OperationsLast filed 4 Sep 2026 | |||||
| Keriann CherofskyOfficerLast filed 31 Jul 2026 | |||||
| Michael J. FedockSVP, Fp&ALast filed 17 Feb 2026 | |||||
| Alistair GrenfellPresident, Commercial SolutionsLast filed 11 Feb 2026 | |||||
| Bernd HaasEVP, AI and Technology SolutionsLast filed 17 Feb 2026 | |||||
| Bhavik PatelOfficerLast filed 4 Aug 2026 | |||||
| Eric SherbetOfficerLast filed 31 Jul 2026 | |||||
| W. Richard StaubOfficerLast filed 4 Aug 2026 | |||||
Companies that share people with IQVIA
Each person's title here, then at the other company.
- The Home Depot HD
- Ari Bousbib: Officer here, Director there
- Eli Lilly LLY
- William G. Kaelin Jr.: Director here, Director there
- ResMed RMD
- Carol Burt: Director here, Director there
Owners and trading
Largest institutional holders
Each fund group's share of IQVIA. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 6 Nov 2025 to 6 Nov 2026
Directors and officers sold $38.0 million of stock in 7 sales and made no open-market purchases in the 12 months to 6 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 2 Sep 2026Sale | James G. BerkshireEVP, Global Infrastructure and Operations | $697K |
| 3 Aug 2026Sale | W. Richard StaubOfficer | $1.3M |
| 31 Jul 2026Sale | Bhavik PatelOfficer | $436K |
| 29 Jul 2026Sale | Ari BousbibOfficer | $26M |
| 29 Jul 2026Sale | Eric SherbetOfficer | $1.2M |
| 29 Jul 2026Sale | Keriann CherofskyOfficer | $137K |
| 18 Dec 2025Sale | Ari BousbibOfficer | $8.1M |
Trades by members of Congress and officials
Trades members of Congress and senior executive branch officials disclosed, including their families'. Amounts are filed as ranges.
Trades from 27 Oct 2023 to 27 Oct 2026
7 people disclosed 17 purchases and 21 sales of IQVIA stock since October 2023.
| Date | Member or official | Amount |
|---|---|---|
| 14 Sep 2026 | Kevin HernHouse, R-OK · Sold | $15K to $50K |
| 8 Sep 2026 | Kevin HernHouse, R-OK · Sold | $1K to $15K |
| 3 Sep 2026 | Kevin HernHouse, R-OK · Sold | $1K to $15K |
| 23 Jun 2026 | Donald J TrumpPresident · Sold | $1K to $15K |
| 22 May 2026 | Donald J TrumpPresident · Sold | $15K to $50K |
| 21 May 2026 | Donald J TrumpPresident · Bought | $1K to $15K |
| 18 May 2026 | Markwayne MullinSecretary · Sold | $50K to $100K |
| 27 Apr 2026 | Donald J TrumpPresident · Sold | $15K to $50K |
| 13 Apr 2026 | Rohit KhannaHouse, D-CA · Sold | $1K to $15K |
| 10 Apr 2026 | Donald J TrumpPresident · Sold | $1K to $15K |
Showing 10 of 38 trades
Workforce and hiring
Workforce
Headcount at 31 Dec 2025
- Employees
- 93,000
Employees, last 10 fiscal years
Up 33% in five years, from 70,000 in 2020 to 93,000 in 2025.
With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, we are dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
Open roles
Jobs listed on IQVIA's careers site, each counted once.
Daily, up to 3 Nov 2026
- Open roles
- 1,898
- On 3 Nov 2026
- Change
- -47
- Down 2.4% since 27 Oct 2026
- Top function
- Sales & Marketing
- 25% of open roles
- Remote
- 8%
- 59% do not say
Open roles in detail
27 Oct 2026 to 3 Nov 2026
Most are in the US (21%), then Germany and China.
| Role | Posted |
|---|---|
| AI Architect - GenAI & Agentic SystemsKochi, India; Bangalore, India | 3 Nov 2026 |
| AnalystPune, Maharashtra, India | 3 Nov 2026 |
| Associate Consultant, Research ConsultingMakati City, Philippines | 3 Nov 2026 |
| Associate/Site Activation ManagerSeoul, Republic of Korea | 3 Nov 2026 |
| Business Development ManagerSeoul, Republic of Korea | 3 Nov 2026 |
| Clinical Advisory AnalystBangalore, India | 3 Nov 2026 |
| Clinical Data Specialist/Assoc Clin Data CoordinatorBangalore, India | 3 Nov 2026 |
| Clinical Supply CoordinatorWarsaw, Poland | 3 Nov 2026 |
| Day | Open roles |
|---|---|
| 3 Nov 2026 | 1,898 |
| 2 Nov 2026 | 1,893 |
| 1 Nov 2026 | 1,901 |
| 31 Oct 2026 | 1,904 |
| 30 Oct 2026 | 1,924 |
| 29 Oct 2026 | 1,928 |
| 27 Oct 2026 | 1,945 |
Timeline
Leadership changes, layoffs and insider sales
7 Nov 2024 to 7 Nov 2026; insider sales from 6 Nov 2025
1 departure and 2 appointments of directors and officers and 4 large insider sales in the last two years.
Insider sales of $1 million or more, and the largest tenth of IQVIA's insider sales.
Events, newest first
- 3 Aug 2026 W. Richard Staub sold $1.3MOfficer
- 29 Jul 2026 Ari Bousbib sold $26MOfficer
- 29 Jul 2026 Eric Sherbet sold $1.2MOfficer
- 18 Dec 2025 Ari Bousbib sold $8.1MOfficer
- 2 Sep 2025 Ronald E. Bruehlman retiredExecutive Vice President and Chief Financial Officer, effective 28 Feb 2026
- 2 Sep 2025 Ronald E. Bruehlman appointedSenior Advisor to the CEO, effective 28 Feb 2026
- 2 Sep 2025 Michael J. Fedock appointedExecutive Vice President and Chief Financial Officer, effective 28 Feb 2026
| Date | Event | Filing |
|---|---|---|
| 3 Aug 2026 | W. Richard Staub sold $1.3MOfficer | Form 4 |
| 29 Jul 2026 | Ari Bousbib sold $26MOfficer | Form 4 |
| 29 Jul 2026 | Eric Sherbet sold $1.2MOfficer | Form 4 |
| 18 Dec 2025 | Ari Bousbib sold $8.1MOfficer | Form 4 |
| 2 Sep 2025 | Ronald E. Bruehlman retiredExecutive Vice President and Chief Financial Officer, effective 28 Feb 2026 | 8-K |
| 2 Sep 2025 | Ronald E. Bruehlman appointedSenior Advisor to the CEO, effective 28 Feb 2026 | 8-K |
| 2 Sep 2025 | Michael J. Fedock appointedExecutive Vice President and Chief Financial Officer, effective 28 Feb 2026 | 8-K |
Not on file: no WARN layoff notices under its own name or a listed subsidiary's since November 2023.